| Literature DB >> 33246302 |
E Murillo-Zamora1, F Aguilar-Sollano2, I Delgado-Enciso3, C M Hernandez-Suarez4.
Abstract
OBJECTIVE: The aim of the study was to identify factors predicting laboratory-positive coronavirus disease 2019 (COVID-19) in pediatric patients with acute respiratory symptoms. STUDYEntities:
Keywords: Adolescent; COVID-19; Child; Odds ratio; Real-time polymerase chain reaction
Mesh:
Year: 2020 PMID: 33246302 PMCID: PMC7584439 DOI: 10.1016/j.puhe.2020.10.012
Source DB: PubMed Journal: Public Health ISSN: 0033-3506 Impact factor: 2.427
Fig. 1Study profile, Mexico 2020. COVID-19; coronavirus disease 2019; SARS-CoV-2; severe acute respiratory syndrome coronavirus 2; qRT-PCR, reverse transcription-quantitative polymerase chain reaction.
Characteristics of the study sample, Mexico 2020.
| Characteristic | Overall | SARS-CoV-2 test result | ||
|---|---|---|---|---|
| Negative | Positive | |||
| Girl | 863 (46.7) | 728 (46.8) | 135 (45.9) | 0.777 |
| Boy | 986 (53.3) | 827 (53.2) | 159 (54.1) | |
| 5.3 ± 5.2 | 5.1 ± 5.0 | 6.5 ± 5.7 | ||
| <3 | 806 (43.6) | 701 (45.1) | 105 (35.7) | |
| 3–5 | 291 (15.7) | 248 (16.0) | 43 (14.6) | |
| 6–12 | 479 (25.9) | 404 (26.0) | 75 (25.5) | |
| 13–15 | 273 (14.8) | 202 (12.9) | 71 (14.2) | |
| <15 | 735 (39.8) | 594 (38.2) | 141 (48.0) | |
| 15–49.9 | 296 (16.0) | 274 (17.6) | 22 (7.5) | |
| 50–99.9 | 94 (5.1) | 87 (5.6) | 7 (2.4) | |
| ≥100 | 724 (39.1) | 600 (38.6) | 124 (42.2) | |
| No | 1552 (83.9) | 1305 (83.9) | 247 (84.0) | 0.969 |
| Yes | 297 (16.1) | 250 (16.1) | 47 (16.0) | |
| No | 1542 (83.4) | 1335 (85.9) | 207 (70.4) | |
| Yes | 307 (16.6) | 220 (14.1) | 87 (29.6) | |
| No | 1211 (65.5) | 998 (64.2) | 213 (72.5) | 0.006 |
| Yes | 638 (34.5) | 557 (35.8) | 81 (27.5) | |
| Mild to moderate | 1148 (62.1) | 932 (59.9) | 216 (73.5) | |
| Severe | 701 (37.9) | 623 (40.1) | 78 (26.5) | |
| Chronic illness (any, yes) | 315 (17.0) | 264 (17.0) | 51 (17.4) | 0.877 |
| Obesity (yes) | 57 (3.1) | 40 (2.6) | 17 (5.8) | 0.003 |
| Asthma (yes) | 104 (5.6) | 93 (6.0) | 11 (3.7) | 0.126 |
| COPD (yes) | 2 (0.1) | 2 (0.1) | 0 (0) | 0.538 |
| Diabetes mellitus (yes) | 13 (0.7) | 10 (0.6) | 3 (1.0) | 0.478 |
| CKD (yes) | 27 (1.5) | 21 (1.4) | 6 (2.0) | 0.366 |
| Immunosuppression (yes) | 159 (8.6) | 132 (8.5) | 27 (9.2) | 0.697 |
| HIV (yes) | 3 (0.2) | 3 (0.2) | 0 (0) | 0.451 |
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; COPD; chronic obstructive pulmonary disease; CKD, chronic kidney disease; HIV, human immunodeficiency virus.
The absolute and relative (%) frequencies are presented, except if other is specified; P-value from chi-squared or t-tests as corresponding.
The arithmetic mean ± standard deviation is presented.
During the flu season 2019––20.
Self-reported; within 14 days before the symptoms onset.
Severe illness was defined by dyspnea requiring hospital admission.
Immunosuppression was referred to any identified cause of the related deficiency except for the personal history of diabetes mellitus, HIV, CKD, or asthma.
Predictors of a positive SARS-CoV-2 test result, Mexico 2020.
| Characteristic | OR (95% CI), | |||||
|---|---|---|---|---|---|---|
| Unadjusted | Adjusted | |||||
| Gender (Ref: girl) | ||||||
| Boy | 1.04 | (0.81–1.33) | 0.777 | 1.08 | (0.83–1.40 | 0.560 |
| Age-group (Ref: | ||||||
| 3–5 | 1.16 | (0.79–1.70) | 0.458 | 1.04 | (0.70–1.55) | 0.841 |
| 6–12 | 1.24 | (0.90–1.71) | 0.184 | 1.10 | (0.78–1.53) | 0.592 |
| 13–15 | 2.35 | (1.68–3.30) | 2.08 | (1.46–2.96) | ||
| Population by place of residence (× 1000; Ref: | ||||||
| 15–49.9 | 0.34 | (0.21–0.54) | 0.34 | (0.21–0.55) | ||
| 50–99.9 | 0.34 | (0.15–0.75) | 0.007 | 0.34 | (0.15–0.76) | 0.008 |
| 100 | 0.87 | (0.67–1.14) | 0.309 | 0.82 | (0.62–1.08) | 0.154 |
| Household contact with a case (Ref: no) | ||||||
| Yes | 2.55 | (1.91–3.40) | 2.27 | (1.68–3.08) | ||
| Sudden symptom onset (Ref: no) | ||||||
| Yes | 0.68 | (0.52–0.90) | 0.006 | 0.80 | (0.60–1.06) | 0.122 |
| Disease severity (Ref: mild to moderate) | ||||||
| Severe | 0.54 | (0.41–0.71) | 0.69 | (0.51–0.92) | 0.012 | |
| Obesity (Ref: no) | ||||||
| Yes | 2.33 | (1.30–4.16) | 0.004 | 2.05 | (1.11–3.79) | 0.022 |
| Asthma (Ref: no) | ||||||
| Yes | 0.61 | (0.32–1.16) | 0.130 | 0.55 | (0.29–1.06) | 0.075 |
| Immunosuppression (Ref: no) | ||||||
| Yes | 1.09 | (0.71–1.68) | 0.697 | 1.22 | (0.79–1.91) | 0.387 |
SARS-CoV-2; severe acute respiratory syndrome coronavirus 2; Ref, reference; OR, odds ratio; CI, confidence interval.
Logistic regression models were used to estimate OR and 95% CI. The listed variables were used to obtain the adjusted estimates. Severe illness was defined by dyspnea requiring hospital admission. Immunosuppression was referred to any identified cause of the related deficiency except for the personal history of diabetes mellitus, human virus immunodeficiency infection, chronic kidney disease, or asthma.